Top 10 Mid Cap Stocks To Own For 2015

Top 10 Mid Cap Stocks To Own For 2015: NuPathe Inc.(PATH)

NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The company?s advanced product candidate includes Zelrix an active single-use transdermal sumatriptan patch that is used for the treatment of migraine. Its proprietary product candidates in preclinical development stage comprise NP201 for the continuous symptomatic treatment of Parkinson?s disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. NuPathe Inc. was founded in 2005 and is headquartered in Conshohocken, Pennsylvania.

Advisors' Opinion:

• [By Tess Stynes]

  Endo Health Solutions Inc.(ENDP) agreed to acquire pharmaceutical company NuPathe Inc.(PATH) for about $105 million to gain the company’s new migraine treatment. Endo will acquire NuPathe for $2.85 per share, a 24% premium to its close of $2.30 on Friday. NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if the company’s migraine treatment Zecuity meets certain sales milestones. NuPathe shares were up 51% at $3.48 in premarket trading.

• [By James E. Brumley]

  It's not hard to find an attractive stock with the market is rallying - the rising tide lifts all stocks. The real test for a ticker is when the whole market is tanking (like Thursday), and a stock manages to make gains against the grain. Enter NuPathe Inc. (NASDAQ:PATH). This little biopharma stock is up 3% today, which isn't much, but given the market it's a virtual windfall. It's the reason for the rally - or lack of a reason to be more specific - that makes PATH such a compelling buy here.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-mid-cap-stocks-to-own-for-20! 15-3.html